Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

1(33.3%)

Phase 1

1(33.3%)

Phase 2

1(33.3%)

3Total

Phase 3(1)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07121478Phase 2Enrolling By Invitation

Patients With High-grade Pancreatic Neuroendocrine Tumors

Role: collaborator

NCT06364150Phase 3Recruiting

Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction

Role: lead

NCT01654601Phase 1Completed

A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg

Role: collaborator

NCT00569504Unknown

Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics

Role: lead

NCT00717509Unknown

Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia

Role: lead

NCT00569764Unknown

Effect on Metabolic Parameters of Abilify in SPR

Role: lead

All 6 trials loaded